H.C. Wainwright maintains Buy on Summit Therapeutics stock

On Thursday, H.C. Wainwright reaffirmed a Buy rating on Summit Therapeutics plc (NASDAQ:SMMT), with a steady price target of $44.00, representing significant upside from the current trading price of $33.23. The stock, which according to InvestingPro data is trading near its 52-week high of $33.89, received this validation following Summit’s Chinese partner, Akeso, sharing promising results from their Phase 3 trial in China for a lung cancer treatment.

Akeso’s recent trial compared ivonescimab combined with chemotherapy against Beigene (NASDAQ:ONC)’s anti-PD-1 with chemo in treating front-line squamous non-small cell lung cancer. The trial’s outcome indicated that ivonescimab, when paired with chemotherapy, significantly outperformed the competing treatment in terms of progression-free survival. Although specific quantitative data was not disclosed, the language used to describe the trial’s success mirrors that of a previous groundbreaking study, which had a substantial positive impact on Summit’s market valuation.

The previous Phase 3 trial, known as HARMONi-2, reported in May 2024 and its results initially propelled Summit’s market capitalization from approximately $1.7 billion to around $7.7 billion. The release of the full dataset in September 2024 further increased the company’s valuation to its current level of $24.51 billion. InvestingPro data shows the stock has delivered an extraordinary 825.63% return over the past year, though skepticism regarding the replicability of the China data in global trials caused some volatility. Notably, the stock’s beta of -0.46 indicates it often moves contrary to broader market trends.

H.C. Wainwright’s note suggests that the recent positive results from the HARMONi-6 trial could alleviate concerns about the ability to reproduce earlier successful data on a global scale. The firm also highlighted the anticipation of an overall survival data readout from the HARMONi-2 trial, expected between the end of 2025 and early 2026, which could serve as a significant catalyst for Summit’s stock performance.

Summit’s share value is closely watched by investors, especially considering the dramatic shifts in market cap following the release of data from previous trials. The reiterated Buy rating and price target reflect H.C. Wainwright’s confidence in the potential of Summit’s ongoing clinical developments. For deeper insights into SMMT’s valuation metrics and growth potential, InvestingPro subscribers can access comprehensive analysis, including 17+ additional ProTips and detailed financial health scores that help evaluate biotech investments more effectively.

In other recent news, Summit Therapeutics has been in the spotlight with several key developments. Cantor Fitzgerald reiterated its Overweight rating on Summit Therapeutics, emphasizing the potential of ivonescimab, a drug in development that could become a new standard for treating non-small cell lung cancer. This follows positive trial results that have met primary endpoints in three large NSCLC trials in China. Additionally, JMP Securities maintained a Market Outperform rating and a $32 price target, highlighting the anticipated Phase 3 HARMONi trial results for ivonescimab, which could significantly impact the company’s stock value by mid-2025.

Truist Securities also expressed confidence in Summit Therapeutics, maintaining a Buy rating and a $35 price target, with a focus on the upcoming results of the HARMONi-2 study. The study is seen as a potential catalyst for the company, with expectations for it to surpass market predictions. In a notable move, Summit Therapeutics’ co-CEO and Chairman, Bob Duggan, exercised warrants to acquire 4 million shares, a decision seen as a positive signal for the company’s stock.

Duggan’s significant ownership and financial backing of Summit Therapeutics have been highlighted as a sign of confidence in the company’s future prospects. His early exercise of warrants, well before their expiration, is considered an atypical and bullish gesture in the biotech industry. Investors are closely watching these developments as they could play a pivotal role in shaping Summit Therapeutics’ trajectory in the oncology market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.